v3.26.1
Segment Information (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting
The following table summarizes information for our single reportable segment, including significant segment expenses:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Revenue$22,974 $15,558 $42,773 $28,286 
Less:
Cost of sales3,268 2,448 6,845 4,672 
Early-stage research and development(1)
1,450 1,156 2,715 2,146 
Late-stage research and development(1)
2,368 2,180 4,613 3,924 
Marketing, selling, and administrative3,430 2,753 6,364 5,221 
Acquired in-process research and development2,776 154 3,360 1,726 
Other segment items(2)
2,587 1,207 4,384 2,177 
Net income$7,095 $5,661 $14,491 $8,420 
Interest expense$345 $249 $677 $493 
Expenditures for long-lived assets(3)
2,906 1,985 5,344 3,502 
(1) Early-stage research and development primarily includes costs incurred from discovery through Phase 2 clinical trials. Late-stage research and development primarily includes costs incurred from Phase 3 clinical trials.
(2) Other segment items primarily include income taxes.
(3) Includes expenditures for property and equipment and computer software costs.